ISMRC 2023 Final Programme

28 Poster Sessions – Wednesday, 3 May 2023 PS-04 04:30 – 06:30 p.m. Liquid Biopsy and Immuno-Oncology and Cancer Immunology Room: Conference 3C – ePoster station 1 Chair: Katja Weisel, Germany PS-04-001 Immune checkpoints and epithelial to mesenchymal transition related mole- cules in triple negative breast cancer patients’ circulating tumor cells and their clinical impact Vasileios Vardas, Greece PS-04-002 Expression of CXCR4, JUNB and PD-L1 in circulating tumor cells isolated from patients with prostate cancer Argyro Roumeliotou, Greece PS-04-003 Detection of circulating tumor cells (CTCs) in patients with metastatic uveal melanoma - a pilot study Shari Schneider, Germany PS-04-004 Circulating microRNAs as predictors of response to therapy in melanoma Luigi Fattore, Italy PS-04-005 The winning liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer Zahra Eslami Samarin, France PS-04-006 Assessment of CTLA4 and TIGIT expres- sion on CTCs and PBMCs of patients with small cell lung cancer (SCLC) Maria A. Papadaki, Greece PS-04-007 Cost-effectiveness analysis of cell-free DNA-based molecular tumor profiling platforms for the detection of EGFR mutations in lung cancer Pim Rozendal, The Netherlands PS-04-008 Early detection of prostate cancer by investigating the host peripheral im- mune response Junjie Chai, United Kingdom PS-04-009 CTC identification enhanced specificity by using a double exclusion biomarker assay Adriana Carneiro, Portugal PS-04-011 Porous bioaffinity membranes for the isolation of circulating tumor cells Thomas Brandstetter, Germany PS-04-012 Mixed MiRNA and Serum-marker Clas- sifier for Prediction of Immunotherapy Response in Liquid Biopsies of Mela- noma Patients Marc Bender, Germany PS-04-013 Circulating miRNA compositions in liq- uid biopsies of melanoma patients as biomarker candidates for progression, PD-L1 status and overall survival Sarah Degenhardt, Germany PS-04-014 ctDNA monitoring of metastatic mela- noma patients receiving immunotherapy Isabel Heidrich, Germany